![](/fileadmin/_processed_/csm_Ipsen_headquarters.__c__Ipsen_SA_865320fa5c.jpg)
Ipsen puts US$1.8bn in pipeline expansion in movement disorders
Under the agreement, Skyhawk will provide its discovery platform for RNA-targeting small molecules across several therapeutic areas, including rare...
![](/fileadmin/_processed_/csm_Peter_Sondermann__c__Tacalyx_d5b3b6d2e0.jpg)
Tacalyx' extends seed capital financing
Tacalyx GmbH, the 2019 spin-out from Peter Seeberger's glycan research group, has doubled its seed funding from €7m to to a bit over €14m to advance...
![](/fileadmin/_processed_/csm_Margrete_Vestager_cutting_red_tape._c__21st_Century_A_S_adbd43f540.jpg)
Danish 21st.BIO A/S opens multipurpose production plant
Today, EU Executive Vice-President Margrete Vestager launched a multi-purpose pilot production facility in Copenhagen, with which 21st.BIO A/S aims...
![](/fileadmin/_processed_/csm_Roche3_cd0afd0272.png)
Obesity: Roche with first clinical data after US$2.7bn deal
Following the acquisition of Carmot Therapeutics in December 2023 for US$2.7bn biobucks (US$400m upfront), Roche has now announced the results of...
![](/fileadmin/_processed_/csm_Evotec_HQ_516a5db450.jpg)
Consortium led by Evotec enters obesity drug space
The newly formed strategic partnership between Evotec SE, Inserm, Lille University Hospital and Inserm Transfert aims to identify novel multimodal...
![](/fileadmin/_processed_/csm_EB224_ECC03_tg_4a0c378aa9.png)
Full house at European Cluster Conference
Compared to the USA and China, EU biotech clusters appear to be dwarfed by the lack of industry-specific support in terms of access to funding,...
![](/fileadmin/_processed_/csm_Apeiron_Board_148036936f.png)
Ligand Pharma to acquire Apeiron Biologics
As part of the US100m acquisition, Ligand Pharmaceuticals Inc has committed to invest up to US$4m in invIOs Holding AG, Apeiron Biologics...